Advertisement

Overall survival with combined nivolumab and ipilimumab in advanced melanoma

Share This Page
Researchers examined 3-year overall survival outcomes in a phase III trial involving patients with advanced melanoma. Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone.

Researchers examined 3-year overall survival outcomes in a phase III trial involving patients with advanced melanoma. Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone. At a follow-up of more than 33 months in a phase I dose-finding study, nivolumab plus ipilimumab resulted in an overall survival rate at 3 years of 68% among patients with advanced melanoma, regardless of whether they had received treatment previously. At a minimum follow-up of 36 months, the median overall survival had not been reached in the nivolumab-plus-ipilimumab group and was 37.6 months in the nivolumab group, as compared with 19.9 months in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.55 [P

Ad Position: 
Bottom Center Aligned
http://www.nejm.org/doi/full/10.1056/NEJMoa1709684?query=featured_home

Advertisement

Related Content

block-views-related-content-block